Straumann Holding
STMN.SW Large CapHealthcare · Medical Instruments & Supplies
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Straumann Holding en bref
Straumann Holding (STMN.SW) is currently trading at 99,88 CHF with a market capitalization of 13,8 Md €. The trailing P/E ratio stands at 44.79x, with a forward P/E of 26.71x. The 52-week range spans from 73,02 CHF to 109,80 CHF ; the current price is 9% below the yearly high. Year-over-year revenue growth stands at +2.2%. The net profit margin stands at 13.66%.
💰 Dividende
Straumann Holding pays an annual dividend of 1,00 CHF per share, representing a yield of 1%. The payout ratio stands at 42.6%.
📊 Avis des analystes
18 analystes évaluent Straumann Holding (STMN.SW) au consensus : Acheter. L'objectif de cours moyen est de 110,33 CHF , soit un potentiel de +10.47% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 85,00 CHF à 130,00 CHF .
Straumann Holding : la thèse d'investissement en détail
Straumann Holding (STMN.SW) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in Switzerland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 70.1%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue growth has slowed to just 2.2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The PEG ratio at 1.49 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 26.71x is meaningfully below the trailing 44.79x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (17.01% ROE)
- Marge brute élevée de 70.1% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 19.35)
- Free cash flow positif
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to market-like volatility.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Straumann Holding?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news